We are live on ! Find out more
KYNB

Kyntra Bio
KYNB

27 hedge funds and large institutions have $7.54M invested in Kyntra Bio in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $7.01M → $7.54M (+$527K)

0.89% less ownership

Funds ownership: 25.57% → 24.68% (-0.89%)

16% less funds holding

Funds holding: 32 → 27 (-5)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
27
Holders Change
-5
Holders Change %
-15.63%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
8
Closed
5
Calls
$729K
Puts
–
Net Calls
+$729K
Net Calls Change
+$81K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$110K
2
Vanguard Capital Management
Vanguard Capital Management
Pennsylvania
+$23.4K
3
TRCT
Tower Research Capital (TRC)
New York
+$5.48K
4
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust
Pennsylvania
+$1.14K
5
HighTower Advisors
HighTower Advisors
Illinois
+$14

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$138K
2
Jane Street
Jane Street
New York
-$82.9K
3
ACM
ADAR1 Capital Management
Texas
-$71K
4
Two Sigma Investments
Two Sigma Investments
New York
-$70.1K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$19.5K

KYNB Hedge Fund Activity: Q2 2026 in Review

27 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2026, worth a combined $7.54M — up 7.5% from $7.01M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of KYNB and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 6 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $110K. The largest seller was UBS Group, cutting an estimated $138K.

  • 27 institutional investors held Kyntra Bio (KYNB) as of Q2 2026, down from 32 in Q1 2026.
  • Funds reported $7.54M of Kyntra Bio stock for Q2 2026, up 7.5% quarter-over-quarter.
  • 1 fund opened new Kyntra Bio positions in Q2 2026 and 5 closed out, a net change of -4 holders.
  • The largest Kyntra Bio buyer in Q2 2026 was GSA Capital Partners, an estimated $110K added.
  • The largest Kyntra Bio seller in Q2 2026 was UBS Group, an estimated $138K sold.

Based on aggregated 13F filings for Q2 2026.